Abbott Expands in Africa, Opens East Africa Headquarters in Kenya

Abbott Expands in Africa, Opens East Africa Headquarters in Kenya

Abbott, a leading
global healthcare company, announced today the opening of its second office in
sub-Saharan Africa at The Watermark – Nairobi Garage Business Park.

The new office will
function as the headquarters for the company’s operations in East Africa and is
intended to support expanded growth opportunities for Abbott, both locally and
in the region.

Abbott’s other office
in sub-Saharan Africa has been based in Johannesburg, South Africa, since 1940.

“The economies of
Kenya and East Africa are growing rapidly and present a tremendous opportunity
for global investment and partnership,” said Maxwell Okello, chief
executive officer, American Chamber of Commerce, Kenya. “We are delighted
to see American companies like Abbott increase their commitment to working with
local governments and the private sector to accelerate the economic growth and
prosperity of the region.”

As the population and
economies of the East African Community continue to grow, its member states are
increasingly focused on strengthening their health systems in order to improve
the health outcomes of their people, their most important resource and the
future of Africa.

“Abbott is deepening
its long-standing commitment to Kenya, and to East Africa as a whole, by
increasing our resources in the region,” said Damian Halloran, vice
president, Infectious Disease-Emerging Markets, Rapid Diagnostics, Abbott.

“We are working
with governments and stakeholders in the region to realize sustainable
healthcare so that people in all places and stages of life can achieve more,
and live not just longer, but better lives.”

With more than 75 years of heritage and an ongoing
commitment to Africa, Abbott is advancing science and technology to constantly
shape new methods of care and improve treatment standards across the
continent. Examples of Abbott’s support of East Africa include:

Kenya – Abbott’s Diagnostics businesses have supplied
millions of rapid tests for HIV, malaria and hepatitis; Abbott core laboratory
and molecular systems at multiple sites analyze high volumes of test samples
that are critical to the health and wellbeing of all Kenyans. In 2016, Abbott’s established Pharmaceuticals business
invested in a local manufacturer, acquiring several products developed for keeping children healthy. Since
2009, Abbott’s nutrition business has provided trusted and
scientifically-proven nutrition solutions to help Kenyans of all ages live
stronger and healthier lives.

Tanzania – Since 2001, Abbott and the Abbott Fund
have worked closely with the government of Tanzania to strengthen the country’s
healthcare system. With more than $130 million invested to date and the
contributions of specialized Abbott experts, this unique public-private
partnership is finding sustainable solutions to critical healthcare challenges
– elevating testing, treatment and care for people across the country. As part
of this initiative, Abbott has helped upgrade patient testing and care at the
country’s largest public hospital and created the first emergency medical
facilities and residency program in East Africa.

Rwanda – Abbott is collaborating with the
Ministry of Health to establish a new model for the decentralization of
healthcare to reach people in rural areas. Abbott is providing technical
expertise and funding a pilot program of second-generation health posts that
will deliver a wide range of primary health services for prenatal and pediatric
care, testing and treatment of infectious diseases, and wound care.

Uganda – Abbott’s diagnostics business is
playing a key role in Uganda’s hepatitis C elimination program and has a
presence in large hospitals, providing results to facilitate prognosis and
diagnosis of various diseases. The National Health Laboratory Service, one of
the largest HIV testing laboratories in the world, operates Abbott’s molecular
systems, which tested more than 900,000 samples last year. Abbott’s rapid
diagnostic tests for HIV, syphilis and malaria are widely used for screening
those diseases; several hundred PIMA analyzers do CD4 testing throughout the